The ACeD-it Study is looking for adult volunteers with celiac disease to join a phase 1b/2 clinical trial. Your participation could make a difference.
This study is investigating KAN-101 for the potential treatment of celiac disease. KAN-101 acts by re-educating T cells, or tolerizing them, so they do not respond to gluten antigens. This is called immune tolerance.
KAN-101 may help patients with celiac disease without interfering with the natural protective functions of the immune system.
The goal of this study is to evaluate the safety and tolerability of KAN-101 in people with celiac disease. This study will also measure how the body responds to the study medication.
- 18-70 years old
- Biopsy-confirmed celiac disease
- On a gluten-free diet for at least the last 12 months
- Anaheim, CA Metropolitan Area
- Atlanta, GA Metropolitan Area
- Columbus, OH Metropolitan Area
- Omaha, NE Metropolitan Area
- Salt Lake City, UT Metropolitan Area
- Paul/Minneapolis/Rochester, MN Metropolitan Area
- More locations coming soon!
Compensation for time and travel is available for eligible participants.
Learn more: Anokion.com/ACeD-it
See if you qualify: iqualify.celiac.org/go/ACeD-it
About the Study Sponsor
Anokion SA, with its wholly owned subsidiaries Kanyos Bio, Inc. and Anokion, Inc., is a clinical-stage Swiss biotechnology company that aims to make a meaningful difference in the lives of patients suffering from autoimmune diseases by restoring normal immune tolerance. The company is focused on both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis, and type 1 diabetes, and recently entered Phase 2 clinical development with its lead program, KAN-101, for celiac disease. Anokion’s distinct approach leverages the company’s immune-based platform, which targets natural pathways in the liver to restore immune tolerance and address the underlying cause of autoimmune disease. For more information, please visit anokion.com.